Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe.
Maria Elisa MancusoGiancarlo CastamanMichal PochopienSamuel AballéaAleksandra DrzewieckaZalmai HakimiJameel NazirFrancis FatoyePublished in: Journal of medical economics (2022)
Based on cost-minimization modeling, rFVIIIFc use for hemophilia A prophylaxis in patients without inhibitors is associated with substantial cost savings in Europe, reflecting not only higher acquisition costs of emicizumab, but also other costs including wastage related to available vial sizes.